- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04849650
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
An Open Label Study of the Pharmacokinetics of Intravenous and Oral Amisulpride in Adults With Severe Renal Impairment and Healthy Control Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be an open-label, non-randomised, pharmacokinetic study in
- 6 adult subjects with severe renal impairment and end-stage renal disease (i.e., eGFR < 30 mL/min/1.73 m2) without dialysis.
- 6 matched healthy subjects (control group).
Each subject will be given a single dose of 10 mg IV Amisulpride, followed by a single dose of 10 mg oral Amisulpride given 24 hours later.
Subjects will be admitted to the clinic on Day -1. Dosing will start the following day (Day 1). Serial blood samples will be taken during Days 1-3 to assess the pharmacokinetics of Amisulpride. Subjects will remain in clinic over the duration of the study and will be discharged when the final blood sample is drawn on Day 3.
The tolerability /safety of Amisulpride will be assessed by clinical chemistry and haematology assessments, vital signs, electrocardiograms (ECG), physical examination and adverse event reporting.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- Panax Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Healthy Subjects
- Age 18 to 75 years of age at time of signing ICF.
- Body mass index (BMI) between 18 and 38 kg/m2.
- Must be willing and able to communicate and participate in the whole study.
- Must provide written informed consent.
- Must agree to use an adequate method of contraception
Healthy as defined by:
- The absence of clinically significant illness and surgery within 4 weeks prior to dosing. Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Principal Investigator;
- The absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic (including cholecystectomy), and metabolic disease;
- The absence of clinically significant history of lactic acidosis and severe hepatomegaly with steatosis;
- The absence of history of suicidal tendency, disposition to seizures, state of confusion, or clinically relevant psychiatric diseases.
- Normal renal function, i.e., eGFR or creatinine clearance ≥ 90 mL/min/1.73 m2 as calculated using the MDRD4 or Cockcroft-Gault equation; at the Principal Investigator's discretion, 24 hour creatinine clearance may be conducted to determine renal function.
- Matched to subjects with severe renal impairment for gender, age (± 10 years), and BMI (± 15%) to the extent possible.
Inclusion Criteria: Renal Impaired Subjects
- Age 18 to 75 years of age at time of signing ICF.
- Body mass index (BMI) between 18 and 38 kg/m2.
- Must be willing and able to communicate and participate in the whole study.
- Must provide written informed consent.
- Must agree to use an adequate method of contraception
- A diagnosis of renal impairment that has been stable, without significant change in overall disease status in the 3 months prior to screening as determined by the Principal Investigator, with no requirement for dialysis, and an eGFR at screening < 30 mL/min/1.73 m2 calculated using the MDRD4 equation.
Exclusion Criteria: Healthy Subjects
- Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
- Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
- Subjects who have previously been enrolled in this study.
- Women who are pregnant or breastfeeding.
- Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
- Allergy to amisulpride or any of the excipients of amisulpride.
- History of any drug or alcohol abuse in the 2 years prior to screening.
- Regular alcohol consumption >21 units per week in the 6 months prior to screening.
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
- History of epilepsy in the 5years prior toscreening.
- History of clinically significant syncope.
- Family history of sudden death.
- Family history of premature cardiovascular death.
Clinically significant history or family history of congenital long QT syndrome (e.g.
Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
- History of clinically significant arrhythmias or ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
- Conditions predisposing the volunteer to electrolyte imbalances (e.g. altered nutritional states, chronic vomiting, anorexia nervosa, bulimia nervosa).
- Clinically significant abnormal biochemistry,haematology or urinalysis at screening as judged by the investigator
- Positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening.
- Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
- Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 2,000 mg per day acetaminophen) or herbal remedies in the 14 days before IMP administration
- Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
- Failure to satisfy the investigator of fitness to participate for any other reason.
Exclusion Criteria: Renal Impaired Subjects
- Subjects who have received any IMP in a clinical research study within the 30 days prior to IMP administration on this study.
- Subjects who are study site, CRO or sponsor employees, or immediate family members of a study site, CRO or sponsor employee.
- Subjects who have previously been enrolled in this study.
- Women who are pregnant or breastfeeding.
- Subjects who have received amisulpride for any indication within the 30 days prior to dosing.
- Allergy to amisulpride or any of the excipients of amisulpride.
- History of any drug or alcohol abuse in the 2 years prior to screening.
- Regular alcohol consumption >21 units per week in the 6 months prior to screening.
- Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
- History of epilepsy in the 5years prior to screening.
- History of clinically significant syncope.
- Family history of sudden death.
- Family history of premature cardiovascular death.
Clinically significant history or family history of congenital long QT syndrome (e.g.
Romano-Ward syndrome, Jervell and Lange-Nielson syndrome) or Brugada's syndrome.
- History of clinically significant arrhythmias or unstable ischaemic heart disease (especially ventricular arrhythmias, atrial fibrillation (AF), recent conversion from AF or coronary spasm).
- Positive drugs of abuse test result, unless caused by a documented prescription drug.
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results at screening.
- Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.
- Administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
- Failure to satisfy the investigator of fitness to participate for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Renal Impairment Subjects
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
|
A single 10mg IV dose of Amisulpride given over 1 minute
A single 10mg dose given as an oral tablet
|
EXPERIMENTAL: Healthy Subjects
10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
|
A single 10mg IV dose of Amisulpride given over 1 minute
A single 10mg dose given as an oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK: Amisulpride plasma exposure (AUC) after a single IV dose
Time Frame: 24 hours
|
Amisulpride plasma exposure after a single IV dose measured as the area under the concentration-time curve (AUC) between study drug administration and the time at which the following-day oral dose of Amisulpride is given
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK: Amisulpride plasma exposure (AUC) after a single oral dose
Time Frame: 24 hours
|
Amisulpride plasma exposure after a single oral dose measured as the area under the concentration-time curve (AUC) from study drug administration extrapolated to infinity
|
24 hours
|
PK: Cmax
Time Frame: 24 hours
|
Peak plasma concentration (Cmax), for both a single IV and single oral dose.
|
24 hours
|
PK: Tmax
Time Frame: 24 hours
|
Time at which peak plasma concentration achieved (Tmax) for both a single IV and single oral dose.
|
24 hours
|
PK: T1/2
Time Frame: 24 hours
|
Half-life (T1⁄2) of both a single IV and single oral dose.
|
24 hours
|
PK: Clearance
Time Frame: 24 hours
|
Clearance of both a single IV and single oral dose.
|
24 hours
|
PK: Vd
Time Frame: 24 hours
|
Volume of distribution (Vd) of both a single IV and single oral dose.
|
24 hours
|
Safety: AE
Time Frame: From first study drug administration until discharge (4 days)
|
Frequency and severity of treatment-emergent adverse events
|
From first study drug administration until discharge (4 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Gabriel Fox, MD, Chief Medical Officer
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Kidney Failure, Chronic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Dopamine Agents
- Dopamine Antagonists
- Antidepressive Agents, Second-Generation
- Amisulpride
Other Study ID Numbers
- DP10026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Disease, End Stage
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Amisulpride IV
-
Seoul National University HospitalUnknownSchizophreniaKorea, Republic of
-
CHA UniversityHandok Inc.UnknownSchizophrenia | Schizophreniform Disorder
-
Mclean HospitalNational Institute of Mental Health (NIMH)Completed
-
Kaohsiung Kai-Suan Psychiatric HospitalTerminated
-
Qilu Pharmaceutical (Hainan) Co., Ltd.Not yet recruiting
-
SanofiCompleted
-
University of California, Los AngelesPoloMar Health LLCNot yet recruiting
-
Simone GrimmBoehringer Ingelheim; Charité Research Organisation GmbHNot yet recruitingMajor Depressive Disorder